Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Slides:

Advertisements

Similar presentations

 SC Guidelines for Diabetes Care Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.

Advertisements

LEADER trial: Primary Outcome

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

A: Kaplan-Meier estimate of time to first LLA

Selected efficacy and safety parameters.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

Group differences (DKA vs

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

Relationships between plasma NEFA concentrations and BMI in two cohorts. Relationships between plasma NEFA concentrations and BMI in two cohorts. Black.

HRs for prostate cancer by medication status.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

The underlying physiological basis of the HOMA model.

Scatterplot of the RR estimates of type 2 diabetes reported in the 15 included studies, and the pooled RR estimates with corresponding 95% CIs for five.

Selection of DFU patients and non-DFU controls

A1C (A) and serum glycated albumin (GA) (B) levels in 47 pregnant women (study 1) divided according to gestational period into group I (21–24 weeks; n.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Effect of empagliflozin on efficacy parameters at week 18.

Comorbid conditions and concomitant medications.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Glycemic control and body weight over 52 weeks.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

Enrollment, outcomes, and pharmacokinetics.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Periods of activation for the knee extensor (VL) and ankle extensor (GN) muscles with respect to foot-step contact (occurring at time zero) during stair.

Plots of average estimated and measured GFR vs

A: Probability of retinopathy-free survival.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Changes in autoantibody titers and GADA IgG1–4 subclass distribution.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)

Complex association between Hb level and GFR, sex, and AER

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.

Presentation transcript:

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Concomitant plasma trough liraglutide concentrations (C) (only liraglutide groups are shown) and dose-corrected plasma trough liraglutide concentrations (D) (only liraglutide groups are shown). Data are means ± SE (A–C) and estimated geometric means with 95% CIs (D) based on data from the PP population. Asterisks (*) in D indicate significance (P < 0.05). Thomas Idorn et al. Dia Care 2016;39:206-213 ©2016 by American Diabetes Association